An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Fulfills DSM-IV criteria for schizophrenia.

• Unable to achieve competitive employment status within the past five years.

• Unable to live independently in the community.

• Maintained on a stable regimen of antipsychotic medication for at least two weeks prior to enrollment.

Exclusion Criteria:

• History of significant hepatic, renal, pulmonary, endocrine, active peptic ulcer disease or cardiovascular disease.

• History of seizure disorder and/or head injury.

• Co-morbid substance use/abuse disorder.

• Received an investigational medication within the previous month.

• Due to the risk of adverse effects on fetal development: women with any risk of becoming pregnant will be excluded from this study.